[go: up one dir, main page]

PE20081485A1 - Derivados de sulfonamida - Google Patents

Derivados de sulfonamida

Info

Publication number
PE20081485A1
PE20081485A1 PE2007001806A PE2007001806A PE20081485A1 PE 20081485 A1 PE20081485 A1 PE 20081485A1 PE 2007001806 A PE2007001806 A PE 2007001806A PE 2007001806 A PE2007001806 A PE 2007001806A PE 20081485 A1 PE20081485 A1 PE 20081485A1
Authority
PE
Peru
Prior art keywords
hydroxy
halogen
indol
aryl
amino
Prior art date
Application number
PE2007001806A
Other languages
English (en)
Inventor
Simona M Ceccarelli
Odile Chomienne
Patrizio Mattei
Ulrike Obst Sander
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20081485A1 publication Critical patent/PE20081485A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE X ES -NHC(O)-, C(O)NH-; Y ES -C(R4R5)-, -C(R4R5)C(R6R7)-, -CR4=CR6, ENTRE OTROS; R1 ES ARILO, HETEROARILO SUSTITUIDOS O NO; R2 ES H, ALQUILO INFERIOR, HIDROXI, HALOGENO, ALCOXI INFERIOR, ENTRE OTROS; R3 ES ARILO, SUSTITUIDO POR 1-3 SUSTITUYENTES SELECCIONADOS ENTRE HALOGENO, CIANO, HIDROXI, ENTRE OTROS; R4, R5, R6 Y R7 SON CADA UNO H, HALOGENO, ALQUILO INFERIOR, HIDROXI, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO (4-{[1-(5-CLORO-2-METOXI-BENCENOSULFONIL)-1H-INDOL-6-CARBOMIL]-AMINO}-FENIL)-ACETICO; ACIDO (2-{[1-(3,5-DIMETIL-BENCENOSULFONIL)-2,3-DIHIDRO-1H-INDOL-6-CARBONIL]-AMINO}-TIAZOL-4-IL)-ACETICO; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PALMITOIL-TRANSFERASA DE CARNITINA DEL HIGADO 1 (L-CPT1), UTILES EN EL TRATAMIENTO DE ENFERMEDADES Y/O TRASTORNOS DE TOLERANCIA A LA GLUCOSA TALES COMO DIABETES Y PATOLOGIAS ASOCIADAS
PE2007001806A 2006-12-21 2007-12-14 Derivados de sulfonamida PE20081485A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06126920 2006-12-21

Publications (1)

Publication Number Publication Date
PE20081485A1 true PE20081485A1 (es) 2008-10-18

Family

ID=39273549

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001806A PE20081485A1 (es) 2006-12-21 2007-12-14 Derivados de sulfonamida

Country Status (17)

Country Link
US (1) US7799933B2 (es)
EP (1) EP2097373B1 (es)
JP (1) JP5089707B2 (es)
KR (1) KR101139211B1 (es)
CN (1) CN101583597B (es)
AR (1) AR064459A1 (es)
AT (1) ATE477240T1 (es)
AU (1) AU2007336364B2 (es)
BR (1) BRPI0720524A2 (es)
CA (1) CA2672761A1 (es)
CL (1) CL2007003697A1 (es)
DE (1) DE602007008467D1 (es)
ES (1) ES2348270T3 (es)
MX (1) MX2009006598A (es)
PE (1) PE20081485A1 (es)
TW (1) TW200833324A (es)
WO (1) WO2008074692A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017827A1 (en) * 2008-08-14 2010-02-18 European Molecular Biology Laboratory 6-substituted 1-sulfonyl-2, 3-dihydro-indole derivatives for the treatment of proliferative diseases
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
JP6063870B2 (ja) 2010-11-08 2017-01-18 ライセラ・コーポレイション ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2846804B1 (en) * 2012-05-08 2017-11-29 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
EP2847198B1 (en) 2012-05-08 2016-12-14 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ror-gamma and the treatment of disease
IN2014DN08025A (es) * 2012-05-08 2015-05-01 Merck Sharp & Dohme
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
WO2015095792A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
CN106132422A (zh) 2014-02-27 2016-11-16 莱斯拉公司 使用视黄酸受体相关孤儿受体γ的激动剂的过继细胞疗法＆相关治疗方法
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
WO2016130818A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
CA2982847A1 (en) 2015-05-05 2016-11-10 Lycera Corporation Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
JP6838004B2 (ja) 2015-06-11 2021-03-03 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患の治療のためのアリールジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
JP2018535958A (ja) 2015-10-27 2018-12-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害薬としての置換インダゾール化合物及びその使用
CA3002853A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
US10344000B2 (en) 2015-10-27 2019-07-09 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
WO2018234807A1 (en) * 2017-06-22 2018-12-27 Curadev Pharma Limited Heterocyclic small molecule modulators of human sting
CN110511182B (zh) * 2019-09-03 2023-01-17 上海昕凯医药科技有限公司 一种连续流反应合成7-硝基-1,2,3,4-四氢喹啉的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7315700A (en) 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Melanin concentrating hormone antagonist
BRPI0610877A2 (pt) 2005-06-06 2010-08-03 Hoffmann La Roche compostos, processo para a manufatura dos compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de l-cpt1 e utilização dos mesmos
AU2006290803B2 (en) 2005-09-15 2009-11-26 F. Hoffmann-La Roche Ag Novel heterobicyclic derivatives useful as inhibitors of liver carnitine palmitoyl transferase

Also Published As

Publication number Publication date
MX2009006598A (es) 2009-07-24
CA2672761A1 (en) 2008-06-26
US7799933B2 (en) 2010-09-21
JP5089707B2 (ja) 2012-12-05
KR101139211B1 (ko) 2012-04-26
CN101583597A (zh) 2009-11-18
EP2097373A1 (en) 2009-09-09
CL2007003697A1 (es) 2008-07-04
ATE477240T1 (de) 2010-08-15
EP2097373B1 (en) 2010-08-11
BRPI0720524A2 (pt) 2014-01-07
JP2010513376A (ja) 2010-04-30
KR20090080567A (ko) 2009-07-24
AU2007336364A1 (en) 2008-06-26
AU2007336364B2 (en) 2012-08-02
WO2008074692A1 (en) 2008-06-26
DE602007008467D1 (de) 2010-09-23
AR064459A1 (es) 2009-04-01
CN101583597B (zh) 2012-07-11
ES2348270T3 (es) 2010-12-02
TW200833324A (en) 2008-08-16
US20080153805A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
PE20081485A1 (es) Derivados de sulfonamida
ES2524045T3 (es) Nuevas amidas y tioamidas heteroaromáticas como plaguicidas
NO20074324L (no) Substituerte arylamin sammensetniger og deres andvendelse som 5-HT6 modulatorer
BRPI0911035A2 (pt) ativadores de pirrolidinona glicoquinase
EA201001595A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
NO20083514L (no) Heterobicykliske sulfonamidderivater for behandling av diabetes
NO20075623L (no) Benzodioksan- og benzodioksolanderivater og deres anvendelse
EA200870460A1 (ru) Производные циклогексилпиразол-лактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1
PE20121127A1 (es) Derivados de piridina y pirazina como moduladores de cinasa de proteina
EA200900658A1 (ru) Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами
CY1111733T1 (el) Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
KR20120114355A (ko) 화합물 및 방법
PE20140968A1 (es) Derivados de benzamida sustituida
EP2776396A2 (en) Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
AR070635A1 (es) DERIVADOS DE PIRIDOPIRAZINONA QUE ESTIMULAN LA SECRECIoN DE INSULINA, MÉTODOS PARA OBTENERLOS, SU USO EN EL TRATAMIENTO DE LA DIABETES Y COMPOSICIONES FARMACEUTICAS.
RU2007148504A (ru) Индановые производные в качестве модуляторов ионных каналов
PE20100093A1 (es) Derivados de acetileno
EA200900797A1 (ru) Способ синтеза производных 3-аминотетрагидрофуран-3-карбоновой кислоты и их применение в качестве лекарственных средств
AR065904A1 (es) Heterociclos como antagonistas de orexina
BR112012017845A2 (pt) novo processo para produção de derivados de benzofenona
AR038704A1 (es) Derivados de tiazol como antagonistas del receptor nyp
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
AR064222A1 (es) 2-imidazoles reguladores de receptores de aminas trazas taar1, medicamentos que los contienen, metodo de preparacion y usos terapeuticos, entre otros, en trastornos asociados al snc.
CN110139857B (zh) 作为吲哚胺2,3-双加氧酶抑制剂的亚砜亚胺、磺酰亚胺酰胺、磺酰二亚胺和二酰亚胺磺酰胺化合物

Legal Events

Date Code Title Description
FD Application declared void or lapsed